Introduction
Inflammatory bowel diseases (IBD), such as Crohn's disease (CD) and ulcerative colitis (UC), are chronic inflammatory disorders of uncertain etiology that mainly involve the gastrointestinal tract and require life-long management. Conventionally, 5-aminosalicylic acids, corticosteroids, and immunomodulators, such as azathioprine and 6-mercaptopurine, have been used for IBD treatment.
In the past few decades, advances in the understanding of the disease mechanism and pathobiology of IBD have yielded insight into mucosal immunity. In this regard, the introduction of antitumor necrosis factor-α (TNF-α) agents has greatly improved management strategies for IBD. Currently, three anti-TNF inhibitors (infliximab, adalimumab, and golimumab) have been approved for treatment of IBD in East Asia ( Table 1 ). The aims of this review paper are to provide an updated overview of the use of anti-TNF in East Asian IBD patients, including complications that may affect their clinical course and strategies to optimize therapy by minimizing complications.
Current anti-tumor necrosis factor therapies in Asian inflammatory bowel disease patients. Discrepancies in therapeutic responses and complication occurrences in IBD populations between Asia and Western countries can exist based on different genetic backgrounds and environmental factors. For instance, some genetic factors and environment are not concordant between Eastern and Western countries. NOD2 and ATG16L1 are predominant genetic factors for CD development in Western patients, but it has no association in Asian CD patients. Instead, TNFSF15 shows predominant association with CD susceptibility in Asians. 1 Therefore, predominant genetic and immunologic factors can affect therapeutic outcomes for different biologics in different populations.
In the early 2000s, several pivotal trials of the approved anti-TNF agents in patients with IBD showed clinical improvement. The efficacy of infliximab in Asian IBD patients was evaluated first in a prospective study in Japan, and the results were concordant with those from Western countries. 2 In this study, both the index of the IBD (IOIBD) and Crohn's Disease Activity Index (CDAI) scores were reduced in infliximab-infused CD patients at week 12. In addition, radiologic and endoscopic improvements were also observed in 63.6% of patients. Similar results were obtained in several retrospective studies of Korean IBD patients that showed the efficacy and safety of infliximab. 3, 4 The long-term outcomes of infliximab have been evaluated in diverse settings with various results. A retrospective evaluation of the efficacy of infliximab for perianal CD patients in maintenance therapy showed a significant improvement of perianal CDAI scores in the short term, while no significant efficacy resulted in patients over the long term. 5 A prospective study in China showed that the group treated with infliximab had favorable long-term efficacy, with significantly decreased CDAI score, C-reactive protein level, and erythrocyte sedimentation rate, compared with the subjects' pretreatment levels (P < 0.01). 6 A retrospective study conducted in Korea compared the efficacy of infliximab with that of cyclosporine in patients with severe steroid-refractory UC. While no difference was found between the treatments in preventing colectomy, infliximab with azathioprine seemed to be superior to cyclosporine monotherapy when it comes to preventing colectomy. 7 Overall therapeutic response rates of infliximab in Asian IBD patients appeared to be similar or higher than those in patients from Western countries.
Intestinal Behçet's disease (BD), which has similar pathogenesis and clinical features with IBD, tends to occur more prevalently in East Asian countries than Western or Mediterranean regions. Thus, optimal therapeutic strategies for intestinal BD are considered more important in East Asia. With regard to intestinal BD, a multicenter in Korea conducted a retrospective study to observe the efficacy of infliximab in intestinal BD patients with 28.6%, 46.2% of clinical remission rates at weeks 4 and 30, respectively. 8 A recently introduced infliximab biosimilar, CT-P13 was approved in South Korea, Europe, and the USA based on similar pharmacokinetic profiles from bioequivalence tests with healthy human participants and randomized clinical trials in patients with ankylosing spondylitis (AS) and rheumatoid arthritis (RA). 9, 10 A retrospective observational study of CT-P13 in Korea 11 demonstrated that CT-P13 was well tolerated in CD patients with 95.5% of clinical response and 77.3% of clinical remission at week 30, while 91.3% and 47.8% of clinical response and clinical remission in UC patients, respectively. Moreover, the Hungarian nationwide cohort study 12 showed 67.2% of clinical response and 53.4% of clinical remission in CD patients and 80%, 68% in UC patients, respectively.
In case of adalimumab, a prospective, randomized, placebocontrolled study was performed on 90 Japanese CD patients to assess the efficacy of adalimumab in terms of clinical remission. 13 The findings were similar to those described in previously published studies from Western countries, showing that the maintenance remission rate at week 52 in Japanese patients with CD was superior in the adalimumab group, compared with the placebo group (38.1% vs 9.1%, respectively, P < 0.05). Recently published Korean data showed that 45.2% of CD patients achieved clinical remission at week 8 and 32.3% maintained remission at week 52. 14 Chang CW et al. demonstrated that adalimumab was effective in inducing and maintaining remission for patients with moderate-to-severe CD in Taiwan. Therefore, the authors argued that despite the stringent criteria for the use of adalimumab in Taiwan, its efficacy could be comparable in patients who did not meet such stringent criteria. 15 Adalimumab has been regarded as a standard therapy for intestinal BD in Japan and Korea since 2014 and 2015, respectively. 16 One prospective study in Japan suggested its therapeutic potential in intestinal BD patients who were refractory to corticosteroid and/or immunomodulator therapies. 17 Because of a higher frequency of intestinal BD in Eastern Asia, anti-TNF therapies had to achieve approval from the corresponding drug regulation counterparts in Japan and Korea. The most recently approved anti-TNF agent, golimumab, was evaluated in double-blind phases 2 and 3 of clinical trials with 1064 adult UC patients (Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment (PURSUIT) study). 18, 19 Until now, clinical data for golimumab in Asian countries have been limited for RA. According to several pivotal studies, onethird of IBD patients were primary non-responders to anti-TNF therapies; and of the responders, approximately 30% of patients ultimately had a subsequent loss of response to anti-TNF agents. Decrease in anti-TNF trough levels and/or the formation of antibodies to anti-TNFs can induce a secondary loss of response. Monitoring of trough levels and anti-drug antibodies can help physicians make an appropriate treatment strategy; such as escalating the dosage or switching to an alternative anti-TNF agent or biologics with different mechanism. 20 Although pharmacokinetic monitoring is considered essential for tailoring a treatment approach, practice data on either secondary loss of response or comparative research on immunogenicity between Eastern and Western countries are currently unavailable.
Major complications of anti-tumor necrosis factor therapies. The decision to use anti-TNFs in the treatment of IBD should be made cautiously, based on the risk-benefit analysis of the drugs' clinical efficacy and potential complications. Current knowledge of anti-TNFs' complications in treating IBD is mostly based on controlled clinical trials and registry studies in Western (2008) BD, Behçet's disease; CD, Crohn's disease; TNF, tumor necrosis factor; UC, ulcerative colitis.
Biologics therapy in East Asia
countries. Data derived from clinical practice in East Asia are still limited.
Major complications of TNF inhibitors are infection and malignancy. Other adverse events include hypersensitivity reactions, dermatological complications, arthralgia, cytopenia, congestive heart failure, demyelinating disease, a lupus-like syndrome, autoimmune liver injury, the induction of autoantibodies, and other systemic side effects. 21, 22 TNF-α plays a crucial role in the maintenance of granulomas and immune responses against viral or intracellular bacterial pathogens; therefore, its inhibition can potentially lead to an increased risk of infections, such as reactivation of latent tuberculosis, hepatitis B, and varicella zoster virus infection. 23 According to a pooled analysis of five pivotal studies (ACCENT I, ACCENT II, SONIC, ACT 1, and ACT 2), 22 infections were found in 846 (49.4%) patients of the infliximab group and in 162 patients (39.9%) of the placebo group (P < 0.001), with symptoms of abscess, bacterial infection, gastroenteritis, and pneumonia. The number of patients experiencing at least one serious infection in the infliximab group was not significantly higher than that of the placebo group (P = 0.427). In this pooled analysis study, malignancy was observed in 13 cases (2 in the placebo group and 11 in the infliximab group). CD patients who received immunomodulator had a higher incidence (95% confidence interval [CI]) of malignancy compared with those without immunomodulator use (1.84 [0. 22, 6 .66]/100 patient-years vs 0.00 [0.00, 0.00]/100 patient-years).
TREAT ™ registry, a 5-year long-term follow-up observation study, demonstrated that disease severity, treatment with narcotic analgesics, prednisolone therapy, and infliximab treatment were significantly associated with serious infections (P < 0.001, P < 0.001, P = 0.002, and P = 0.006, respectively). 21 In the TREAT ™ registry, the most common serious infections included pneumonia, abdominal abscess, catheter sepsis, sepsis, cellulitis, central line infection, and gastroenteritis. In a post-marketing surveillance study of IBD patients who were administered a biosilmilar of infliximab, CT-P13 in Korea, treatment-related adverse events were observed in 18.1%, 16.7%, and 26.9% of CD patients, fistulizing CD patients, and UC patients, respectively, during 30 weeks of follow-up period. 24 Complications of adalimumab therapy were not significantly different from those of other anti-TNF therapies. Because of its similar mechanism to other anti-TNF-α drugs that affect cellmediated immunity, its common side effects were infections, both serious and nonserious. As reported in previous clinical trials, adalimumab could increase the risk of serious infections. Injection site reactions were specific to subcutaneous therapy, and were generally mild. Rare complications included opportunistic infections, such as tuberculosis, demyelinating disorders, lymphomas, malignancies, lupus-like syndrome, and either the development or the worsening of multiple sclerosis and other neurological diseases. 25, 26 However, the overall rate of complications was similar to that of the placebo group.
Although anti-TNF therapies are considered effective in treating psoriasis, they have the potential to paradoxically increase the development and severity of psoriasis. In 18 cases of anti-TNF-α-induced psoriasis in IBD patients extracted by a literature review, 27 the new onset of palmoplantar psoriasis occurred during treatment with anti-TNF-α agent, mainly between the third and fourth infusion of the biologic. Nearly 88% (16 out of 18) of the symptoms in these cases resolved after the withdrawal of infliximab, or after switching to other biologics. Some in vitro studies have demonstrated that the prohibition of TNF-α may induce uncontrolled and unlimited production of IFN-α, which can cause psoriatic lesions. 28 Of the complications mentioned earlier, several concerns have been raised in patients from the Asia-Pacific region.
Tuberculosis. Anti-TNF therapy can increase the risk of tuberculosis and the reactivation of latent tuberculosis. The mechanism underlying this effect is the crucial role that TNF-α plays in the immune response to Mycobacterium tuberculosis, which is gathering inflammatory cells to the site of infection by producing chemokines and vascular adhesion molecules in T cells and macrophages. 29 Therefore, the inhibition of TNF-α can result in a higher incidence of tuberculosis, after the initiation of biologic therapy in IBD patients who were latently infected with M. tuberculosis. The developments of the tuberculin skin test (TST) and the bacille Calmette-Guerine vaccine in 1910 have reduced the prevalence of tuberculosis. The TST and interferon (IFN)-γ release assays (IGRA) are the most pragmatic screening measures for tuberculosis infection. TST is a rapid, inexpensive, and widely available detection method, whereas IGRA has more specificity over TST based on assays using specific M. tuberculosis antigens, such as early secreted antigen 6 (ESAT6) and culture filtrate protein 10 (CFP 10), albeit at a higher material cost. In addition, new diagnostic measures, such as liposomal agglutination-based methods, are continuously being developed.
However, tuberculosis still remains a major health problem in the Asia-Pacific region. For instance, in South Korea, there were 9350 cases of newly diagnosed pulmonary tuberculosis, and 6987 cases of extrapulmonary tuberculosis in 2014. In the same year, the incidence rate per 100 000 individuals was 86 in South Korea, 167 in India, and 68 in China, which were significantly high compared with 9 in Belgium and 3.1 in the USA. 30 Of the entire global total, Asian countries of India, Indonesia, and China had the most number of cases (23%, 10%, and 10%, respectively). Several retrospective studies have used a nationwide health database, or single/multicenter clinical data, to assess the incidence of tuberculosis in patients who received anti-TNF therapy. Initially, patients with RA who were treated with anti-TNF-α in Korea were evaluated based on data from the Korean National Tuberculosis Association. The risk of tuberculosis occurrence was 30.1-fold (95% CI, 7.4-122.3) in RA patients, while nonexposure to TNF blockers resulted in an 8.9-fold increased risk (95% CI, 4.6-17.2) compared with that of the general population. 31 According to a recent study based on data collected by Korea's Health Insurance Review and Assessment Service between 2005 and 2009, IBD patients had a remarkably higher incidence of tuberculosis than patients with other diseases, such as RA, AS, and psoriatic arthritis. Specifically, there were 3710 cases of tuberculosis per 100 000 person-years (95% CI, 2297-5672) in IBD patients, while there were 934 cases (23-5207) in psoriatic arthritis patients, 715 cases (522-957) in AS patients, and 1143 cases (797-1591) in RA patients. 32 Multicenter studies using longitudinal cohorts have also shown that biologics could increase the risk of tuberculosis infection. 33, 34 One possible explanation for the higher incidence of tuberculosis in IBD patients who are on anti-TNF therapy could be the higher dose of the drug used during the procedure.
In order to maintain the therapeutic efficiency and safety of anti-TNF agents, while minimizing the risk of tuberculosis infection, it is mandatory to screen for latent tuberculosis infection before performing anti-TNF therapy. Careful history-taking and physical examination, chest X-ray, and TST/IGRA test are recommended, particularly in regions where tuberculosis is endemic. Generally, it is recommended to initiate anti-TNF therapy for latent tuberculosis infection (LTBI) patients about 3-4 weeks after LTBI treatment initiation. In addition, continuous surveillance, for the detection of tuberculosis infection, is needed for IBD patients receiving long-term anti-TNF therapy. It cannot be overemphasized that patients with negative results during LTBI screening should still be carefully scrutinized for development of tuberculosis; this is because more than half of the patients on anti-TNF agents develop tuberculosis after the initial therapy, even if the LTBI screening test was negative. When a patient on anti-TNF therapy develops tuberculosis, the treatment should be suspended and immediately replaced with anti-tuberculosis treatment. Once the appropriate anti-tuberculosis therapy is complete, it is generally regarded as safe to resume anti-TNF agents.
Viral hepatitis infection. Anti-TNF alpha inhibitors can be beneficial for hepatitis B virus (HBV) treatment; however, HBV reactivation is also a well-known complication related to immunosuppressive and anti-TNF-α targeted therapies. Previous research has shown that TNF-α level is elevated in the liver and the sera of patients with either acute or chronic viral hepatitis. 35 Specifically, it can stimulate CD8+ T cells in response to HBV. In addition, the simultaneous release of TNF-α and IFN-γ downregulates HBV gene expression and induces the apoptosis of HBV-infected hepatocytes. 36 Therefore, TNF inhibitors may induce the replication of HBV by allowing the virus to escape the endogenous antiviral immune response. HBV infection is a major factor in the development of chronic liver disease and hepatocellular carcinoma with a high economic burden. Moreover, acute HBV reactivation because of immunosuppressive therapy in IBD patients can be life threatening.
Viral hepatitis is endemic in East Asian countries. Out of nearly 350 million people diagnosed with HBV infection worldwide, an estimated 75% of them live in Asia. 37 The highest prevalence of HBV infection in Asian countries was reported in East Asia, and endemicity of hepatitis B surface antigen (HBsAg) was also found in Central Asia. 38 Two recent studies in South Korea have shown higher percentages of HBsAg positivity in IBD patients (3.7-4.1%), compared with those of patients from Western countries. 39, 40 Significant numbers of chronic and past HBV infections (6.7% and 28.5%, respectively) were also observed in a study of 267 Chinese IBD patients. 41 The prevalence of hepatitis infection is known to depend on individual risk factors and the background of disease prevalence. Also, in general, there is no difference in HBV infection rates between IBD patients and individuals without IBD, even in HBV-endemic areas. However, a retrospective study in China showed that present and past HBV infections were more prevalent in IBD patients (40.62%) than in non-IBD patients (27.58%) (P = 0.00). 42 Hepatitis B virus reactivation or infection with anti-TNF therapy can be characterized in two phases. First, while biologics are being administered, a rise in viremia associated with a decrease in immune-mediated hepatic lesions can increase the risk of infection. Second, after the cessation of therapy, immunologic rebound with the destruction of virus-infected hepatocytes can occur. To minimize these risks in IBD patients undergoing biologic therapy, screening tests and vaccination are recommended. The American College of Gastroenterology, American College of Rheumatology, and European Crohn's and Colitis Organization (ECCO) have recommended that IBD patients undergo a hepatitis B screening test and vaccination prior to anti-TNF therapy, if such methods have not already been performed or if the patient has risk factors. [43] [44] [45] The risk factors include a history of corticosteroid use, as well as combination therapy with multiple drugs (e.g. AZA/6MP and corticosteroids). In addition, a better response to HBV vaccination is anticipated in IBD patients who are treated without immunosuppressants and/or anti-TNF inhibitors, compared with those treated with these agents. 46 The response rate of IBD patients to HBV vaccination is lower than that for normal controls. The low response rates to vaccination and revaccination in IBD patients is possibly because of the disease itself, or the anti-TNF therapy. According to the most recent prospective surveillance study of hepatitis in IBD patients undergoing anti-TNF therapy, 47 vaccination before anti-TNF treatment resulted in a fivefold better response than vaccination during anti-TNF treatment (odds ratio = 5.22). Thus, the updated ECCO guidelines recommend receiving universal testing (HBsAg, anti-HBs, and anti-HBc) and HBV vaccination immediately after IBD diagnosis. 48 Several studies on patients undergoing anti-TNF therapy demonstrated that the prophylactic use of anti-viral drugs, such as lamivudine for latent HBV infection, is recommended during the course of anti-TNF therapy. 49 However, viral resistance can develop in up to 30% of patients after a year with the prolonged use of lamivudine. In addition, the emergence of resistance has been associated with viral reactivation in patients on long-term anti-TNF therapy. 50 The association between hepatitis C virus (HCV) infection and anti-TNF therapy in IBD patients remains a major problem in patients receiving immunosuppressant therapy, although there has been limited research on the matter. 51 In Korea, the prevalence of HCV infection has gradually increased between 2005 and 2012. 52 Furthermore, 10% of the cases of liver cirrhosis and 12-17% of the cases of hepatocellular carcinoma were associated with HCV. 53 Several studies have suggested that the HCV core protein had the potential to inhibit the TNF-mediated apoptotic signaling pathway. 54 Therefore, anti-TNF therapies could generally improve the clinical course of IBD without worsening chronic HCV infection. However, given the immunosuppressant mechanism of anti-TNF therapy, it could also increase the risk of HCV infection and reactivation. Although there are no current guidelines for the prevention of HCV reactivation in IBD patients undergoing anti-TNF therapy, careful follow ups of liver function and viral status are required.
Malignancy. Patients with IBD involve risk factors for the development of intestinal malignancy, which is associated with the extent of the disease, duration, and age at diagnosis. 55 Theoretically, the administration of anti-TNF-α also raises concerns for the development of malignancies, such as lymphoma, although TNF-α has been shown to limit the growth of tumors in several animal models. 56 The malignancy rates of patients treated with anti-TNF therapies have not been consistent. It is difficult to estimate the potential risk of malignancy in IBD, which is confounded by the fact that biologics are usually used in more severe patients who are being treated concurrently or with immunomodulators.
A pooled clinical analysis of IBD patients who were treated with infliximab showed a similar incidence of malignancy compared with the placebo group. The two groups also had similar incidences of lymphoma and non-lymphoma malignancies. 22 However, two retrospective studies showed an increased risk of non-melanoma skin cancer and melanoma in patients receiving biologic treatment than in those not receiving biologics (internal rate of return: 1.64; 95% CI, 1.51-1.78, odds ratio: 1.88; 95% CI = 1.08-3.29, respectively). 57, 58 In a recent study in Japan, 28 cases of hematologic malignancies were detected out of 36 939 IBD patients. Out of the total number of patients, 37.5% had a history of infliximab use (6/16), although this was not statistically significant. 59 These results showed that a large prospective safety cohort is needed to compare the risk of malignancy in IBD patients undergoing treatment with anti-TNF therapy. In addition, further research is required to define the risk factors associated with malignancy or tumor growth, including advanced age, high doses of anti-TNF agents, the duration of treatment, and the history of malignancy. To reduce of the risk of developing hepatosplenic T-cell lymphoma, the ECCO guidelines on extraintestinal malignancies recommend that young IBD patients avoid prolonged combination therapy of anti-TNF therapy and thiopurines for more than 2 years. 60 In addition, biologics can increase the risk of melanoma. Although regular dermatological screening and protection against UV radiation are recommended in Caucasians, no such guideline exists for Asian patients with IBD. Rather, current guidelines for malignancy in Asian patients focus on the surveillance of colorectal cancer. Therefore, guidelines for IBD patients must be established for other type of cancers that are prevalent in Asia, such as gastric cancer or thyroid cancer.
Immunogenicity to vaccination. To prevent a number of infectious diseases during immunosuppressive treatment, effective vaccines should be considered prior to initiating biologic therapies. Ideally, all patients should receive vaccinations at the time of diagnosis. The types of vaccinations indicated for IBD patients include those for general health maintenance, influenza (trivalent inactivated vaccine), human papilloma virus, pneumococcal polysaccharide vaccine, hepatitis B vaccine, and varicella zoster virus. 61, 62 However, several studies have shown that IBD patients are inadequately vaccinated, especially those who are immunocompromised because of corticosteroid or immunosuppressive therapy. 61 The mechanism of anti-TNF agents in the immune response after vaccination is not clear. They may interfere with the immune response to vaccines by reducing the migration and maturation of dendritic cells into highly costimulatory antigenpresenting cells or by inhibiting the activation of T cells and the secretion of IFN-γ. In addition, disruption of the organization of normal lymphoid architecture of the germinal centers, as well as Table 2 Prevention and treatment guidelines for common complications of anti-TNF treatment 45, 48 Prevention Treatment
Hepatitis B -To determine HBV status, screening test should be given for HBV (HBsAg, anti-HBAbs, and anti-HBcAb) at diagnosis of IBD.
-Nucleotide/nucleoside analogs are recommended.
-HBV vaccination is recommended in all HBV anti-HBcAb seronegative patients with IBD.
-Entecavir and tenefovir are the other preferred anti-virals for IBD patients because of their rapid onset of action, highest anti-viral potency, and low incidence of resistance. -Viremia (HBV-DNA) should be assessed every 2-3 months, but antiviral therapy is not recommended unless HBV-DNA is detected.
-No established treatment for acute HBV infection, but nucleotide/nucleoside treatment is also recommended.
Tuberculosis -Scrutinized history-taking, especially regarding tuberculosis risk factors, is needed.
-Suspension of anti-TNF treatment -Chest X-ray, tuberculin skin test, and/or interferon-gamma release assay test are recommended.
-4-drug regimen: isoniazid, rifampin, pyrazinamide, and either ethambutol or streptomycin -In case of LTBI, at least 3-4 weeks of LTBI treatment is recommended prior to anti-TNF treatment.
-Restarting guideline of anti-TNF therapies are yet to be established.
-Chemoprophylaxis should follow appropriate local guidelines. Influenza -Influenza vaccine (trivalent inactivated vaccine) should be given once a year.
-Immunosuppressed patients with a laboratory diagnosis of influenza should receive prompt treatment early in the course of illness. -Live attenuated vaccine is not recommended.
- patients who were administered PSV-23 vaccine, the infliximab group had a significantly lower vaccine response rate, compared with the control group (58% vs 89%; P = 0.008). Assessing the amount of anti-pneumococcal antibodies, the infliximab group showed a 2.69-fold increase in antibody titer, compared with a 5.71-fold increase in the control group. 64 These results were reaffirmed in a recent prospective study of Korean CD patients, which found that the female sex and anti-TNF therapy were significant nonresponse predictors to pneumococcal polysaccharide vaccination (P = 0.015, P = 0.048, respectively). 65 PCV-13 vaccine, in which polysaccharides are conjugated to an immunogenic carrier protein, is expected to be more immunogenic than PPV23. 66 In a randomized prospective study of two types of pneumococcal vaccines in patients with CD, 67 PCV13 recipients undergoing immunosuppressive therapy showed higher antibody responses to serotype 23 F than PPV23 recipients. However, whether pneumonia is more prevalent in IBD patients or in the general populations in East Asia has yet to be elucidated. In addition, the effectiveness of vaccinations in reducing the regional prevalence of pneumonia should also be confirmed.
In a recent study on the immunogenicity of influenza vaccine in IBD patients on biologics, 68 Launay O et al. reported that anti-TNF treatment, with or without immunomodulators, reduced the immune response to influenza vaccine (for strains A/H3N2, A/H1N12007, and A/H1N1v2009) with less persistence of seroprotection after vaccination. An impaired immune response among anti-TNF treated patients was associated not only with anti-TNF and combinatory immunomodulation but also with anti-TNF monotherapy. In another randomized trial assessing the immunogenicity of the influenza vaccine at both the time of the initial infliximab infusion and midway through therapy, 69 serologic protection was not significantly different between vaccination during IFX treatment with H1N1, H3N2, and influenza B (P = 0.8, 0.5, and 0.2, respectively). The immunogenic responses were also similar. Thus, the timing of influenza vaccine during infliximab infusion schedule does not affect the immunogenicity of the vaccine. A better understanding of vaccine immune response in immune-mediated diseases, which includes IBD, is needed in future clinical trials. Having experienced several pandemics, human influenza virus, and other respiratory diseases are emerging threats in East Asia. A recent study on the global diversity of the influenza A virus found that nucleotide substitution rates for influenza subtypes were higher in East Asian countries than in North America. 70 This underscores the need for increased attention to proper and timely vaccinations for IBD patients, especially in East Asia.
Conclusion
Anti-TNF alpha inhibitors significantly improved clinical outcomes in patients with IBD. Moderately to severely ill patients who are refractory or intolerant to conventional therapy had favorable outcomes on anti-TNF-α. However, reduced treatment responses, rare but severe complications, and the considerable costs of biologics were all barriers to their wider use in the clinical setting. Thus, close monitoring and identification of individual risk factors for complications are important principles in biologic therapy (Table 2) . Notably, medical environment and the prevalence of infectious diseases remain challenges for IBD specialists in the Asia-Pacific region. Special issues related to biologic therapy for IBD include infection, vaccination, and malignancy surveillance (Table 3 and Fig. 1 ). The treatment strategy for biologics should be tailored to meet the medical environment and patient in certain ethnic groups.
